Navigation Links
Trubion Announces Presentations at Upcoming Investor Conferences
Date:2/3/2009

SEATTLE, Feb. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update and an overview of the company at two upcoming investor conferences in February and March:

-- Feb. 10: BIO CEO & Investor Conference at the Waldorf Astoria, 301 Park Ave., in New York City. Peter Thompson, M.D., FACP, president, CEO and chairman, is scheduled to present at 9 a.m. EST. A replay of the webcast will be available one hour after the presentation has ended at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2079646.

-- March 18: Invest Northwest Investor Conference at the Bell Harbor International Convention Center, 2211 Alaskan Way, in Seattle. Michelle Burris, chief financial officer and senior vice president, is scheduled to present at 10:50 a.m. PST. A replay of the webcast will be available after the presentation at http://www.wsw.com/webcast/in7/trbn/.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and infl
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... -- Personal Genome Diagnostics Inc. (PGDx), today announced that ... in genomic analysis of defined cancer subtypes to ... Medicines.  PGDx is an innovator in conducting patient-specific ... and Blueprint Medicines is an expert in developing ... patient population. "This collaboration brings together ...
(Date:5/21/2013)... May 21, 2013 Revolutionary Science, the ... colony counter, announced today that they have expanded their ... , the IncuCount, IntelliCount, InCount and ImpressCount. These ... are especially useful in food microbiology and pharmaceutical manufacturing. ... updated look. A bright white enclosure with jet ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... trial indicate statistically significant reduction in recurrences ... ... JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. (Nasdaq: MEDX ... Medical School (UMMS) today,announced that a Phase 2 trial of an ...
... Cepheid (Nasdaq:,CPHD) today announced that it ... Stretton Scientific Limited, a privately held distributor ... in,Stretton, England. Stretton Scientific currently distributes Cepheid,s,SmartCycler(R) ... products, to,a broad group of medical customers ...
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
Cached Biology Technology:Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6
(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... birds often choose their mates based on fancy feathers. ... likely to follow their noses to the right mate. ... Harvard researcher Katherine McAuliffe, whose review of evidence for ... issue of The Quarterly Review of Biology . ...
... that belongs to the oldest living family of jawed vertebrates, ... discovery, published in the March 2009 issue of Genome ... evolved in early vertebrates over the last 450 million years ... vertebrate like the elephant shark had the potential for color ...
... a novel regulator of p53, an important protein that safeguards ... March 17, 2009 issue of the journal Genes & ... this microRNA keeps the level of p53 low to avoid ... damaged, the microRNA level is reduced to allow an increase ...
Cached Biology News:Female mammals follow their noses to the right mates 2Elephant shark genome sequence leads to discovery of color perception in deep-sea fish 2Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers 2
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
Mycoplasma tested...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
Biology Products: